Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1826 in NSCLC
NCT06844474Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1826 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Incidence and severity of adverse events / serious adverse events at 2 years and Overall response rate at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
SHR-1826
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06844474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844474.